Pioneering novel approaches to increase access for patients worldwide
•
2 likes•255 views
Sandoz aims to pioneer novel approaches to increase access to high-quality healthcare for patients worldwide. In 2015, Sandoz reached 520 million patient lives and their aspiration is to reach one billion. Biosimilars are key to their goal of increasing access, as they can play a transformational role by generating savings for healthcare systems, increasing supply of medicines, and improving patient access to life-saving treatments.
Report
Share
Report
Share
Download to read offline
Recommended
Sandoz in Africa - a global leader
Sandoz is a global leader in generic pharmaceuticals and is part of the Novartis Group. In 2011, Sandoz had sales of $9.5 billion and reached over 400 million patients worldwide. Sandoz operates in 140 countries with around 25,000 employees and has a portfolio of over 1,100 compounds and 23,500 stock-keeping units. The document discusses Sandoz's leadership in various therapeutic areas and technologies. It also highlights Sandoz's commitment to growth in Africa through partnerships and projects aimed at improving patient care.
Eyeforpharma 2017
Richard Francis, Division Head and CEO, Sandoz presentation to Eyeforpharam conference 2017 on healthcare system sustainability and the role of generics and biosimilars
Sandoz: #SandozHACk #tweetchat
On November 9, 2016, Sandoz held a #tweetchat focused on ways to increase access to medicines and the major challenges facing healthcare systems over the next 5-10 years.
Sandoz Company Presentation
Sandoz reached 520 million patients worldwide in 2015 and aims to reach one billion patients by expanding access to medicine. The presentation discusses the global challenge of access to healthcare, with over 2 billion people unable to access needed medicines. Sandoz is uniquely positioned within Novartis to help solve the access challenge through its broad portfolio, focus on priority markets, and leadership in generics, biosimilars, and anti-infectives.
The Biosimilar Market Leader’s Perspective
At least 400 million people worldwide lack access to essential health services and 2 billion cannot afford the medicines they need. Meanwhile, the global cost of healthcare has jumped to 6.5 trillion US dollars. Access is a huge and complex issue, which affects both developing and developed countries.
Today Carol Lynch, our Global Head of Biopharmaceuticals, gave a keynote address to the European Biosimilars Group highlighting how biosimilars can help transform patient outcomes and calling for all stakeholders to work together to build trust and confidence. You can read the presentation here
Expanding Sandoz leadership in biosimilars
A short presentation on the challenges and opportunities of biosimilars and the role they can play in access to medicine
14. Dr. Thomas Kirchlechner - Sandoz Biopharmaceuticals Development
14. Dr. Thomas Kirchlechner - Sandoz Biopharmaceuticals DevelopmentInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
“Challenges of biosimilar product development and experience gained”
Shows the development process for biosimilars, focusing specifically on the company’s experienceOriginators and Princeps: How to face Biosimilars and Generics
Concerning the levers a originators producer can put in place to face the biosimilars competition and maintain his position, benchmarking on biosimilars, generics (13 companies from 2000 to 2015) and the results of our interview allow us to observe 10 levers:
Price Prescription
Patent Market saturation
Legal action New market
Cooperation Environmental strategy
Product Brand strategy
Recommended
Sandoz in Africa - a global leader
Sandoz is a global leader in generic pharmaceuticals and is part of the Novartis Group. In 2011, Sandoz had sales of $9.5 billion and reached over 400 million patients worldwide. Sandoz operates in 140 countries with around 25,000 employees and has a portfolio of over 1,100 compounds and 23,500 stock-keeping units. The document discusses Sandoz's leadership in various therapeutic areas and technologies. It also highlights Sandoz's commitment to growth in Africa through partnerships and projects aimed at improving patient care.
Eyeforpharma 2017
Richard Francis, Division Head and CEO, Sandoz presentation to Eyeforpharam conference 2017 on healthcare system sustainability and the role of generics and biosimilars
Sandoz: #SandozHACk #tweetchat
On November 9, 2016, Sandoz held a #tweetchat focused on ways to increase access to medicines and the major challenges facing healthcare systems over the next 5-10 years.
Sandoz Company Presentation
Sandoz reached 520 million patients worldwide in 2015 and aims to reach one billion patients by expanding access to medicine. The presentation discusses the global challenge of access to healthcare, with over 2 billion people unable to access needed medicines. Sandoz is uniquely positioned within Novartis to help solve the access challenge through its broad portfolio, focus on priority markets, and leadership in generics, biosimilars, and anti-infectives.
The Biosimilar Market Leader’s Perspective
At least 400 million people worldwide lack access to essential health services and 2 billion cannot afford the medicines they need. Meanwhile, the global cost of healthcare has jumped to 6.5 trillion US dollars. Access is a huge and complex issue, which affects both developing and developed countries.
Today Carol Lynch, our Global Head of Biopharmaceuticals, gave a keynote address to the European Biosimilars Group highlighting how biosimilars can help transform patient outcomes and calling for all stakeholders to work together to build trust and confidence. You can read the presentation here
Expanding Sandoz leadership in biosimilars
A short presentation on the challenges and opportunities of biosimilars and the role they can play in access to medicine
14. Dr. Thomas Kirchlechner - Sandoz Biopharmaceuticals Development
14. Dr. Thomas Kirchlechner - Sandoz Biopharmaceuticals DevelopmentInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
“Challenges of biosimilar product development and experience gained”
Shows the development process for biosimilars, focusing specifically on the company’s experienceOriginators and Princeps: How to face Biosimilars and Generics
Concerning the levers a originators producer can put in place to face the biosimilars competition and maintain his position, benchmarking on biosimilars, generics (13 companies from 2000 to 2015) and the results of our interview allow us to observe 10 levers:
Price Prescription
Patent Market saturation
Legal action New market
Cooperation Environmental strategy
Product Brand strategy
Francine Nieto Quintiles IMS Presentation
The global OTC market reached $112 billion in sales as of mid-2016, with developing regions driving most of the growth. Major trends include a shift toward health and wellness, the rise of connected consumers, and increasing interest in herbal and natural remedies. The document outlines routes to growth for OTC companies through innovation, geographic expansion, focus on high-growth categories, and potential M&A activity.
GenSearch - Value in Healthcare: Who Holds the Key?
GenSearch is a pan European Executive Search and HR services consultancy firm dedicated to the Life Sciences.
Its focus covers the Pharmaceutical, Medical Devices and BioTech industries. In the course of its day-to-day activity, the firm has gradually acquired a deep interest and insight into the transformation of the European healthcare systems and their stakeholders.
This white paper was created following the Life Science Talks event “Value in Healthcare: Who holds the key?” in June 2016.
The speakers were invited to present their day-to-day challenges, and to give specific examples of how their companies are currently adapting to evolving market needs.
MSD Policy Passport on pharmaceutical innovation - October 2023 v2.pdf
Presentation of the key public policies at the source of all medicines ever developed and a review of about 40+ key issues often raised when discussing pharmaceutical policy in a crisp format with references supporting the presentation.
European Healthcare Innovation & Investment Learning from successes and navig...
We have heard all about the unstable policy landscape in the U.S., the unprecedented levels of capital pumped into the market and the mega deals - but how much do we really know about the European space?
Who are the most prominent investors actively investing in healthcare in Europe?
What elements of policy and regulation in Europe support and impede scaling of new and novel healthcare approaches?
What are some of the most notable investments and partnerships and what can we learn from them?
Beyond investment what is important in Europe?
Nhp corporate presentation-june2019(1)
The document discusses Mondias Natural Products, a company that specializes in developing and commercializing botanical products for agriculture and healthcare. It highlights several of Mondias' products in development areas like biopesticides and sleeping aids, which target large and growing markets. The summary provides an overview of Mondias' strategy to generate revenue through its Holizen division, pursue partnerships, and expand its product portfolio and sales reach over the next few years.
Strategic Management presentation for a Pharmaceutical Industry
The document provides an overview of Sanofi, a major global pharmaceutical company, including:
- Its operations in over 100 countries with over 100,000 employees and 19,300 scientists
- Its business entities and therapeutic expertise in the Philippines, focusing on cardiovascular diseases, diabetes, oncology, and other areas
- Details on its organizational structure, vision and mission statements, research and development process, product types, supply chain, and performance in the diabetes drug category market
SPHS at World Water Week
World Water Week is the annual focal point for the globe’s water issues, organized by SIWI. Every year, experts, practitioners, decision-makers, business innovators and young professionals from a range of sectors and countries come to Stockholm to network, exchange ideas, foster new thinking and develop solutions to the most pressing water-related challenges of today.
Dr. Rosemary Kumwenda, the UNDP EECA HIV, Health, and Development Regional Team Leader and SPHS Coordinator, delivered a presentation introducing what the SPHS initiative does to green the global healthcare sector.
Zoonotic Disease Treatment Market 10-Year Market Forecast and Trends Analysis...
This document summarizes a report on the global zoonotic disease treatment market. Zoonotic diseases are those spread between animals and humans. The market is driven by factors like population growth, urbanization, and increased consumption of animal proteins. However, lack of disease awareness, high research costs, and drug prices restrain the market. The market is expected to grow due to rising meat consumption and income levels in developing nations. North America currently dominates the market but Asia Pacific is expected to experience increased zoonotic disease prevalence due to poor sanitation. The report provides an overview, key drivers and restraints, regional analysis, and profiles major market players.
Empowering Indian pharmaceutical industry to lead globally.
Interlink's knowledge team was privileged to undertake preparation of white paper
on “empowering Indian pharmaceutical industry to lead globally”.
Kybora EM_ABI 2016
The document discusses trends in life science investing globally. It notes that while US and European healthcare IPO issuance and market volatility has fluctuated between 2010-2016, overall investment in healthcare IPOs and M&A transactions has generally increased. The document then outlines trends showing increased investment in biotech and life sciences globally, including rising investments in China and more venture capital going to biopharma companies in their Series A rounds. It concludes that given increasing medical spending, longer life expectancies and rapid innovation, it is a good time to start new life sciences businesses.
Precision medicines – delivering to patients
The document discusses the challenges and opportunities for precision medicines and new distribution models. Precision medicines are often high cost with low volumes, requiring new infrastructure, equipment, and handling procedures to maintain cold chains, sterile environments, and track batch recalls. This is driving non-traditional models involving increased homecare delivery, patient support programs, pharmacist education and roles, and outcomes monitoring. It also creates opportunities for new big data through improved adherence tracking, which can provide insights for manufacturers, pharmacies, and consumers if shared through data and service-oriented platforms extending from pallet to patient. Overcoming these challenges requires trust, care, partnership, dedication and innovation across the healthcare system.
Nuclear Medicine World Market report and Directory 2016
This 990-page report provides strategic intelligence on the global nuclear medicine market. It includes profiles of 370 radiopharmaceuticals and radionuclides, 170 companies and institutions, and analyzes market trends, projections, and opportunities. The global nuclear medicine market is expected to reach $25 billion by 2030, driven by 13% annual growth in diagnostic radiopharmaceuticals and 27% growth in therapeutic radiopharmaceuticals. While nuclear medicine currently represents less than 1% of the pharmaceutical industry, new radiotherapeutics could reach blockbuster status before 2025. The report is an essential source of information for businesses and investors in the nuclear medicine industry.
7o Pharma & Health Conference, Νίκος Κωστάρας
Ομιλία – παρουσίαση: Νίκος Κωστάρας, Γενικός Διευθυντής Ελλάδας, IMS Health
Τίτλος παρουσίασης: «Μείωση Δαπάνης μέσω αύξησης Πληροφόρησης»
Case for emerging 9 sustaining oncology innovation
The document discusses the challenges facing major oncology innovator companies as their traditional cash cow drugs lose market share to biosimilars. It argues that innovators need to look beyond traditional Western markets and consider partnering with emerging markets like India to strengthen their healthcare systems and generate sustainable revenues. This could help build new cash cows to fund future innovation while improving access in populations with high cancer rates. The document outlines how an integrated approach with partners across government, non-profits and hospitals could work to mutually benefit patients, innovators and healthcare systems in emerging markets.
Megafund for Rare Diseases
This document discusses the concept of "megafunds" to help fund research and development for rare diseases. It notes that current sources of funding like venture capital and philanthropic venture capital are not enough to develop treatments for the over 7,000 known rare diseases. It proposes creating large pooled investment funds or "megafunds" that would attract funding from institutional investors by issuing bonds or debt backed by the intellectual property of a portfolio of drug development programs. This could open access to a larger pool of capital to fund more rare disease research more efficiently and at a reduced risk level through diversification. It provides examples of past proposals and discussions around this concept as a potential new model to help bridge the "valley of death"
MSD AIA Forum - 2009 Brochure
Report capturing the content of the MSD Access, Innovation, and Affordability Forum organized by MSD in 2007 (Munich) and 2008 (Istanbul). The report was produced for the third edition of the AIA Forum, which took place in Warsaw in 2009.
MEDraysintell radioactivity used in medicine, a land of opportunities - janua...
MEDraysintell radioactivity used in medicine, a land of opportunities - janua...Paul-Emmanuel Goethals
Radiation is used widely in medicine and represents opportunities for growth.
Nuclear medicine, proton therapy, and brachytherapy are niche markets that currently represent less than 0.1% of global health expenditures but are expected to grow more than twice as fast as the overall health market. The document discusses market sizes and growth forecasts for various radiation therapy and diagnostic modalities.
MEDraysintell provides strategic intelligence on radiation healthcare markets through numerous reports and can customize intelligence to specific areas or modalities.Annual review 2017
Arterial’s annual review of global healthcare is considered by many family offices, research analysts and wealth management groups to be the leading, authoritative report on the economic and political drivers and activity within the life science sector.
Arterial provide readers with an in-depth analysis of the past years’ investment trends within biotech, medtech and pharmaceuticals. The report analyses deal flow between private and institutional investors, identifies trends by sub sector, product and geographical / regional placement and concludes with our predictions for the year and decades ahead.
Brachytherapy report and directory Edition 2016
Brachytherapy is a niche market but should grow more than twice as fast as the global health market.
The global brachytherapy industry is evaluated in a new and updated MEDraysintell’s report and directory, providing in a 340-page document a complete description of the radionuclides and devices used in brachytherapy, and a detailed profile of 62 companies and institutions active in this field around the world.
GSIPA2M, Plenary 1, Return to Marrakech - Andrew Hill
Prices versus costs of medicines - what could be done?
Presented by Andrew Hill, University of Liverpool, UK.
More Related Content
Similar to Pioneering novel approaches to increase access for patients worldwide
Francine Nieto Quintiles IMS Presentation
The global OTC market reached $112 billion in sales as of mid-2016, with developing regions driving most of the growth. Major trends include a shift toward health and wellness, the rise of connected consumers, and increasing interest in herbal and natural remedies. The document outlines routes to growth for OTC companies through innovation, geographic expansion, focus on high-growth categories, and potential M&A activity.
GenSearch - Value in Healthcare: Who Holds the Key?
GenSearch is a pan European Executive Search and HR services consultancy firm dedicated to the Life Sciences.
Its focus covers the Pharmaceutical, Medical Devices and BioTech industries. In the course of its day-to-day activity, the firm has gradually acquired a deep interest and insight into the transformation of the European healthcare systems and their stakeholders.
This white paper was created following the Life Science Talks event “Value in Healthcare: Who holds the key?” in June 2016.
The speakers were invited to present their day-to-day challenges, and to give specific examples of how their companies are currently adapting to evolving market needs.
MSD Policy Passport on pharmaceutical innovation - October 2023 v2.pdf
Presentation of the key public policies at the source of all medicines ever developed and a review of about 40+ key issues often raised when discussing pharmaceutical policy in a crisp format with references supporting the presentation.
European Healthcare Innovation & Investment Learning from successes and navig...
We have heard all about the unstable policy landscape in the U.S., the unprecedented levels of capital pumped into the market and the mega deals - but how much do we really know about the European space?
Who are the most prominent investors actively investing in healthcare in Europe?
What elements of policy and regulation in Europe support and impede scaling of new and novel healthcare approaches?
What are some of the most notable investments and partnerships and what can we learn from them?
Beyond investment what is important in Europe?
Nhp corporate presentation-june2019(1)
The document discusses Mondias Natural Products, a company that specializes in developing and commercializing botanical products for agriculture and healthcare. It highlights several of Mondias' products in development areas like biopesticides and sleeping aids, which target large and growing markets. The summary provides an overview of Mondias' strategy to generate revenue through its Holizen division, pursue partnerships, and expand its product portfolio and sales reach over the next few years.
Strategic Management presentation for a Pharmaceutical Industry
The document provides an overview of Sanofi, a major global pharmaceutical company, including:
- Its operations in over 100 countries with over 100,000 employees and 19,300 scientists
- Its business entities and therapeutic expertise in the Philippines, focusing on cardiovascular diseases, diabetes, oncology, and other areas
- Details on its organizational structure, vision and mission statements, research and development process, product types, supply chain, and performance in the diabetes drug category market
SPHS at World Water Week
World Water Week is the annual focal point for the globe’s water issues, organized by SIWI. Every year, experts, practitioners, decision-makers, business innovators and young professionals from a range of sectors and countries come to Stockholm to network, exchange ideas, foster new thinking and develop solutions to the most pressing water-related challenges of today.
Dr. Rosemary Kumwenda, the UNDP EECA HIV, Health, and Development Regional Team Leader and SPHS Coordinator, delivered a presentation introducing what the SPHS initiative does to green the global healthcare sector.
Zoonotic Disease Treatment Market 10-Year Market Forecast and Trends Analysis...
This document summarizes a report on the global zoonotic disease treatment market. Zoonotic diseases are those spread between animals and humans. The market is driven by factors like population growth, urbanization, and increased consumption of animal proteins. However, lack of disease awareness, high research costs, and drug prices restrain the market. The market is expected to grow due to rising meat consumption and income levels in developing nations. North America currently dominates the market but Asia Pacific is expected to experience increased zoonotic disease prevalence due to poor sanitation. The report provides an overview, key drivers and restraints, regional analysis, and profiles major market players.
Empowering Indian pharmaceutical industry to lead globally.
Interlink's knowledge team was privileged to undertake preparation of white paper
on “empowering Indian pharmaceutical industry to lead globally”.
Kybora EM_ABI 2016
The document discusses trends in life science investing globally. It notes that while US and European healthcare IPO issuance and market volatility has fluctuated between 2010-2016, overall investment in healthcare IPOs and M&A transactions has generally increased. The document then outlines trends showing increased investment in biotech and life sciences globally, including rising investments in China and more venture capital going to biopharma companies in their Series A rounds. It concludes that given increasing medical spending, longer life expectancies and rapid innovation, it is a good time to start new life sciences businesses.
Precision medicines – delivering to patients
The document discusses the challenges and opportunities for precision medicines and new distribution models. Precision medicines are often high cost with low volumes, requiring new infrastructure, equipment, and handling procedures to maintain cold chains, sterile environments, and track batch recalls. This is driving non-traditional models involving increased homecare delivery, patient support programs, pharmacist education and roles, and outcomes monitoring. It also creates opportunities for new big data through improved adherence tracking, which can provide insights for manufacturers, pharmacies, and consumers if shared through data and service-oriented platforms extending from pallet to patient. Overcoming these challenges requires trust, care, partnership, dedication and innovation across the healthcare system.
Nuclear Medicine World Market report and Directory 2016
This 990-page report provides strategic intelligence on the global nuclear medicine market. It includes profiles of 370 radiopharmaceuticals and radionuclides, 170 companies and institutions, and analyzes market trends, projections, and opportunities. The global nuclear medicine market is expected to reach $25 billion by 2030, driven by 13% annual growth in diagnostic radiopharmaceuticals and 27% growth in therapeutic radiopharmaceuticals. While nuclear medicine currently represents less than 1% of the pharmaceutical industry, new radiotherapeutics could reach blockbuster status before 2025. The report is an essential source of information for businesses and investors in the nuclear medicine industry.
7o Pharma & Health Conference, Νίκος Κωστάρας
Ομιλία – παρουσίαση: Νίκος Κωστάρας, Γενικός Διευθυντής Ελλάδας, IMS Health
Τίτλος παρουσίασης: «Μείωση Δαπάνης μέσω αύξησης Πληροφόρησης»
Case for emerging 9 sustaining oncology innovation
The document discusses the challenges facing major oncology innovator companies as their traditional cash cow drugs lose market share to biosimilars. It argues that innovators need to look beyond traditional Western markets and consider partnering with emerging markets like India to strengthen their healthcare systems and generate sustainable revenues. This could help build new cash cows to fund future innovation while improving access in populations with high cancer rates. The document outlines how an integrated approach with partners across government, non-profits and hospitals could work to mutually benefit patients, innovators and healthcare systems in emerging markets.
Megafund for Rare Diseases
This document discusses the concept of "megafunds" to help fund research and development for rare diseases. It notes that current sources of funding like venture capital and philanthropic venture capital are not enough to develop treatments for the over 7,000 known rare diseases. It proposes creating large pooled investment funds or "megafunds" that would attract funding from institutional investors by issuing bonds or debt backed by the intellectual property of a portfolio of drug development programs. This could open access to a larger pool of capital to fund more rare disease research more efficiently and at a reduced risk level through diversification. It provides examples of past proposals and discussions around this concept as a potential new model to help bridge the "valley of death"
MSD AIA Forum - 2009 Brochure
Report capturing the content of the MSD Access, Innovation, and Affordability Forum organized by MSD in 2007 (Munich) and 2008 (Istanbul). The report was produced for the third edition of the AIA Forum, which took place in Warsaw in 2009.
MEDraysintell radioactivity used in medicine, a land of opportunities - janua...
MEDraysintell radioactivity used in medicine, a land of opportunities - janua...Paul-Emmanuel Goethals
Radiation is used widely in medicine and represents opportunities for growth.
Nuclear medicine, proton therapy, and brachytherapy are niche markets that currently represent less than 0.1% of global health expenditures but are expected to grow more than twice as fast as the overall health market. The document discusses market sizes and growth forecasts for various radiation therapy and diagnostic modalities.
MEDraysintell provides strategic intelligence on radiation healthcare markets through numerous reports and can customize intelligence to specific areas or modalities.Annual review 2017
Arterial’s annual review of global healthcare is considered by many family offices, research analysts and wealth management groups to be the leading, authoritative report on the economic and political drivers and activity within the life science sector.
Arterial provide readers with an in-depth analysis of the past years’ investment trends within biotech, medtech and pharmaceuticals. The report analyses deal flow between private and institutional investors, identifies trends by sub sector, product and geographical / regional placement and concludes with our predictions for the year and decades ahead.
Brachytherapy report and directory Edition 2016
Brachytherapy is a niche market but should grow more than twice as fast as the global health market.
The global brachytherapy industry is evaluated in a new and updated MEDraysintell’s report and directory, providing in a 340-page document a complete description of the radionuclides and devices used in brachytherapy, and a detailed profile of 62 companies and institutions active in this field around the world.
GSIPA2M, Plenary 1, Return to Marrakech - Andrew Hill
Prices versus costs of medicines - what could be done?
Presented by Andrew Hill, University of Liverpool, UK.
Similar to Pioneering novel approaches to increase access for patients worldwide (20)
GenSearch - Value in Healthcare: Who Holds the Key?
GenSearch - Value in Healthcare: Who Holds the Key?
MSD Policy Passport on pharmaceutical innovation - October 2023 v2.pdf
MSD Policy Passport on pharmaceutical innovation - October 2023 v2.pdf
European Healthcare Innovation & Investment Learning from successes and navig...
European Healthcare Innovation & Investment Learning from successes and navig...
Strategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical Industry
Zoonotic Disease Treatment Market 10-Year Market Forecast and Trends Analysis...
Zoonotic Disease Treatment Market 10-Year Market Forecast and Trends Analysis...
Empowering Indian pharmaceutical industry to lead globally.
Empowering Indian pharmaceutical industry to lead globally.
Nuclear Medicine World Market report and Directory 2016
Nuclear Medicine World Market report and Directory 2016
Case for emerging 9 sustaining oncology innovation
Case for emerging 9 sustaining oncology innovation
MEDraysintell radioactivity used in medicine, a land of opportunities - janua...
MEDraysintell radioactivity used in medicine, a land of opportunities - janua...
GSIPA2M, Plenary 1, Return to Marrakech - Andrew Hill
GSIPA2M, Plenary 1, Return to Marrakech - Andrew Hill
Recently uploaded
The Best Ayurvedic Antacid Tablets in India
Treat the symptoms of indigestion, heartburn and stomach reflux with the 10 Best Ayurvedic Antacid Tablets in India.
Top-Vitamin-Supplement-Brands-in-India List
Swisschem Dermacare provides the Top 10 Vitamin Supplement Brands in India. To know more about us give us call at our official number
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxMGM SCHOOL/COLLEGE OF NURSING
Identification and nursing management of congenital malformations Role of Mukta Pishti in the Management of Hyperthyroidism
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
micro teaching on communication m.sc nursing.pdf
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Knee anatomy and clinical tests 2024.pdf
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...chandankumarsmartiso
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun Women Seeking Service
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Best Ayurvedic medicine for Gas and Indigestion
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeProf. Marcus Renato de Carvalho
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Recently uploaded (20)
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Pioneering novel approaches to increase access for patients worldwide
- 1. Pioneering novel approaches to increase access for patients worldwide Richard Francis, Division Head & CEO Sandoz Schaftenau, Austria June 17, 2016 Sandoz
- 2. Sandoz “We discover new ways to improve and extend people’s lives...” “ ...by pioneering novel approaches to help people around the world access high- quality healthcare” This is how we contribute to improving society’s ability to support growing healthcare needs Our purpose is to increase access for patients Business Use Only1
- 3. Sandoz Business Use Only2 ...and our aspiration is to reach ONE BILLION Sandoz reached 520 million patient lives in 2015
- 4. Sandoz Biosimilars are key to increasing access to life-saving medicines Business Use Only3 Oncology Respiratory Biosimilars Anti-infectives Region growth drivers OTC Sandoz FY 2015 sales Of 11 filings already completed2 Q1 2016 cc growth vs PY Sandoz access drivers USD 772m 6 +50% 1. Including retail business 2. 11th filing expected – infliximab
- 5. Sandoz Biosimilars can play a transformational role in healthcare Business Use Only4 €49-98B Expected cumulative savings from biosimilars 2016-2020 in US+EU51 Generate savings for healthcare systems ~104% Increase in standard units of filgrastim in the UK from 2008-2014 (post biosimilar launch)1 Improve patient access Sandoz is committed to driving access to biosimilars and life-saving medicines 1. IMS Institute for Healthcare Informatics: Delivering on the Potential of Biosimilar Medicines. Date of Report: Mar 2016.